Pedro L Vera Selected Research

protease-activated receptor 4

1/2019	Spinal macrophage migration inhibitory factor and high mobility group box 1 mediate persistent bladder pain.
12/2017	Macrophage migration inhibitory factor mediates protease-activated receptor 4-induced bladder pain through urothelial high mobility group box 1.
5/2017	Disulfide high mobility group box-1 causes bladder pain through bladder Toll-like receptor 4.
1/2016	Protease-Activated Receptor 4 Induces Bladder Pain through High Mobility Group Box-1.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pedro L Vera Research Topics

Disease

21	Inflammation (Inflammations) 03/2019 - 08/2003
9	Pain (Aches) 01/2022 - 01/2015
7	Cystitis 03/2019 - 08/2003
7	Hypersensitivity (Allergy) 01/2019 - 04/2004
6	Neoplasms (Cancer) 10/2011 - 07/2004
4	Hyperalgesia 01/2022 - 10/2004
4	Edema (Dropsy) 05/2017 - 01/2004
3	Prostatic Neoplasms (Prostate Cancer) 05/2011 - 07/2005
2	Neuralgia (Stump Neuralgia) 03/2019 - 01/2019
2	Interstitial Cystitis (Interstitial Cystitis, Chronic) 03/2019 - 01/2018
2	Urinary Bladder Neoplasms (Bladder Cancer) 04/2010 - 07/2004
2	Adenocarcinoma 07/2005 - 07/2004
2	Neurogenic Inflammation 10/2004 - 04/2004
1	Skin Neoplasms (Skin Cancer) 01/2019
1	Carcinogenesis 04/2010
1	Body Weight (Weight, Body) 07/2008
1	Urinary Tract Infections (Urinary Tract Infection) 04/2006
1	Abnormal Reflex (Hyperreflexia) 12/2004
1	Neurogenic Urinary Bladder (Bladder, Neurogenic) 04/2004
1	Ganglion Cysts (Ganglion) 01/2004

Drug/Important Bio-Agent (IBA)

30	Macrophage Migration-Inhibitory FactorsIBA 01/2022 - 08/2003
14	CytokinesIBA 12/2010 - 08/2003
7	Proteins (Proteins, Gene)FDA Link 01/2015 - 08/2003
6	HMGB1 Protein (HMG1)IBA 01/2022 - 01/2016
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2019 - 01/2008
5	Substance PIBA 06/2009 - 04/2004
4	protease-activated receptor 4IBA 01/2019 - 01/2016
4	Messenger RNA (mRNA)IBA 11/2010 - 08/2003
3	macrophage migration inhibitory factor receptorIBA 01/2021 - 05/2008
3	Peptides (Polypeptides)IBA 01/2019 - 01/2016
3	Glycyrrhizic Acid (Glycyrrhizin)IBA 01/2019 - 01/2016
3	Peptide Hydrolases (Proteases)FDA Link 10/2018 - 09/2006
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 10/2004 - 08/2003
2	DisulfidesIBA 12/2017 - 05/2017
2	Thrombin FDA Link 12/2010 - 04/2010
2	Nerve Growth Factor (NGF)IBA 11/2010 - 10/2004
2	LigandsIBA 01/2008 - 12/2006
2	alpha 1-inhibitor 3IBA 09/2006 - 07/2005
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022
1	Butylated Hydroxyanisole (BHA)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2019
1	Analgesics (Analgesic Drugs)IBA 01/2019
1	Phosphodiesterase 5 InhibitorsIBA 01/2019
1	MIF098IBA 10/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	Proteinase-Activated ReceptorsIBA 12/2017
1	Sulfhydryl Compounds (Thiols)IBA 05/2017
1	ethyl 6- (N- (2- chloro- 4- fluorophenyl)sulfamoyl)cyclohex- 1- ene- 1- carboxylateIBA 05/2017
1	Toll-Like Receptor 4IBA 05/2017
1	FPS-ZM1IBA 05/2017
1	Carrier Proteins (Binding Protein)IBA 01/2016
1	ChromatinIBA 01/2016
1	plerixafor FDA Link 01/2015
1	Atrial Natriuretic Factor (ANF)IBA 05/2011
1	Hormones (Hormone)IBA 05/2011
1	atrial natriuretic factor receptor AIBA 05/2011
1	Natriuretic PeptidesIBA 05/2011
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 11/2010
1	Biological ProductsIBA 11/2010
1	Endoplasmic Reticulum Chaperone BiPIBA 06/2009
1	Lidocaine (Xylocaine)FDA LinkGeneric 07/2008
1	Phentolamine (Z-Max)FDA LinkGeneric 07/2008
1	Atropine FDA LinkGeneric 07/2008
1	Propranolol (Inderal)FDA LinkGeneric 07/2008
1	Neurotransmitter Agents (Neurotransmitter)IBA 07/2008
1	Hexamethonium (Hexamethonium Bromide)IBA 07/2008
1	Chemokine ReceptorsIBA 01/2008
1	AndrogensIBA 12/2006
1	Formaldehyde (Formol)FDA Link 12/2004
1	Phenobarbital (Luminal)FDA Link 10/2004
1	NeuropeptidesIBA 04/2004
1	EndotoxinsIBA 01/2004

Therapy/Procedure

3	Intravesical Administration 01/2019 - 05/2017
1	Aftercare (After-Treatment) 01/2015
1	Therapeutics 12/2006